HUE049591T2 - Makrociklusos MCL-1 inhibitorok rák kezelésére - Google Patents
Makrociklusos MCL-1 inhibitorok rák kezeléséreInfo
- Publication number
- HUE049591T2 HUE049591T2 HUE17720720A HUE17720720A HUE049591T2 HU E049591 T2 HUE049591 T2 HU E049591T2 HU E17720720 A HUE17720720 A HU E17720720A HU E17720720 A HUE17720720 A HU E17720720A HU E049591 T2 HUE049591 T2 HU E049591T2
- Authority
- HU
- Hungary
- Prior art keywords
- macrocyclic
- treating cancer
- mcl1 inhibitors
- mcl1
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662326156P | 2016-04-22 | 2016-04-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE049591T2 true HUE049591T2 (hu) | 2020-09-28 |
Family
ID=58664658
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE17720720A HUE049591T2 (hu) | 2016-04-22 | 2017-04-21 | Makrociklusos MCL-1 inhibitorok rák kezelésére |
Country Status (37)
Country | Link |
---|---|
US (4) | US9840518B2 (hu) |
EP (1) | EP3445767B1 (hu) |
JP (1) | JP6894449B2 (hu) |
KR (1) | KR102388208B1 (hu) |
CN (1) | CN109071566B (hu) |
AR (1) | AR108301A1 (hu) |
AU (1) | AU2017252222B2 (hu) |
BR (1) | BR112018070677B1 (hu) |
CA (1) | CA3020378A1 (hu) |
CL (1) | CL2018002410A1 (hu) |
CO (1) | CO2018008759A2 (hu) |
CR (1) | CR20180499A (hu) |
CY (1) | CY1123186T1 (hu) |
DK (1) | DK3445767T3 (hu) |
DO (1) | DOP2018000222A (hu) |
EA (1) | EA036551B1 (hu) |
ES (1) | ES2791319T3 (hu) |
HR (1) | HRP20200673T1 (hu) |
HU (1) | HUE049591T2 (hu) |
IL (1) | IL262237B (hu) |
LT (1) | LT3445767T (hu) |
MA (1) | MA44721B1 (hu) |
ME (1) | ME03729B (hu) |
MX (1) | MX2018012711A (hu) |
NI (1) | NI201800093A (hu) |
PE (1) | PE20181803A1 (hu) |
PH (1) | PH12018502227A1 (hu) |
PL (1) | PL3445767T3 (hu) |
PT (1) | PT3445767T (hu) |
RS (1) | RS60257B1 (hu) |
SG (1) | SG11201805838UA (hu) |
SI (1) | SI3445767T1 (hu) |
SV (1) | SV2018005742A (hu) |
TN (1) | TN2018000319A1 (hu) |
TW (1) | TWI742074B (hu) |
WO (1) | WO2017182625A1 (hu) |
ZA (1) | ZA201807766B (hu) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11066416B2 (en) | 2016-02-04 | 2021-07-20 | The Johns Hopkins University | Rapafucin derivative compounds and methods of use thereof |
CA3013650A1 (en) | 2016-02-04 | 2017-08-10 | The Johns Hopkins University | Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof |
MX2018009408A (es) | 2016-02-04 | 2018-11-09 | Univ Johns Hopkins | Rapaglutinas, nuevos inhibidores de transportadores de glucosa (glut) y uso de los mismos. |
KR102388208B1 (ko) | 2016-04-22 | 2022-04-18 | 아스트라제네카 아베 | 암을 치료하기 위한 거대 환형 mcl1 억제제 |
CN109715632B (zh) | 2016-05-19 | 2021-10-26 | 拜尔公开股份有限公司 | 大环吲哚衍生物 |
TWI781996B (zh) * | 2017-03-31 | 2022-11-01 | 瑞典商阿斯特捷利康公司 | 合成mcl-1抑制劑之方法 |
TW201904976A (zh) * | 2017-03-31 | 2019-02-01 | 瑞典商阿斯特捷利康公司 | Mcl-1抑制劑及其使用方法 |
EP3988555A1 (en) | 2017-08-15 | 2022-04-27 | AbbVie Inc. | Macrocyclic mcl-1 inhibitors and methods of use |
WO2019035899A1 (en) * | 2017-08-15 | 2019-02-21 | Abbvie Inc. | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE |
EP3710449B1 (en) | 2017-11-17 | 2022-07-06 | The Broad Institute, Inc. | Macrocyclic fluorine substituted indole derivatives as mcl-1 inhibitors, for use in the treatment of cancer |
WO2019096905A1 (en) * | 2017-11-17 | 2019-05-23 | Bayer Aktiengesellschaft | Macrocyclic chlorine substituted indole derivatives |
EP3710447A1 (en) * | 2017-11-17 | 2020-09-23 | Bayer Aktiengesellschaft | Aryl annulated macrocyclic indole derivatives |
TWI810220B (zh) * | 2017-11-17 | 2023-08-01 | 德商拜耳廠股份有限公司 | 經取代之巨環吲哚衍生物 |
TW201932473A (zh) | 2017-11-17 | 2019-08-16 | 美商博德研究所有限公司 | 巨環吲哚衍生物 |
EP3710450A1 (en) | 2017-11-17 | 2020-09-23 | Bayer Aktiengesellschaft | Macrocyclic chlorine substituted indole derivatives |
TW202014184A (zh) * | 2018-04-30 | 2020-04-16 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合 |
CN112533929B (zh) * | 2018-09-30 | 2022-09-16 | 福建盛迪医药有限公司 | 吲哚类大环衍生物、其制备方法及其在医药上的应用 |
TWI810397B (zh) | 2018-11-14 | 2023-08-01 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
CN111205309B (zh) * | 2018-11-21 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 吲哚类大环衍生物、其制备方法及其在医药上的应用 |
CN110845520B (zh) * | 2018-11-22 | 2021-04-13 | 苏州亚盛药业有限公司 | 作为mcl-1抑制剂的大环吲哚 |
CN112204036B (zh) * | 2019-01-23 | 2022-12-27 | 苏州亚盛药业有限公司 | 作为mcl-1抑制剂的大环稠合的吡唑 |
EP3924358A4 (en) * | 2019-03-08 | 2023-07-05 | Zeno Management, Inc. | MACROCYCLIC COMPOUNDS |
TW202106693A (zh) * | 2019-04-30 | 2021-02-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 吲哚類大環衍生物、其製備方法及其在醫藥上的應用 |
CA3138058A1 (en) | 2019-05-20 | 2020-11-26 | Matthew T. Burger | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
EP3986902B1 (en) * | 2019-06-21 | 2024-01-24 | Janssen Pharmaceutica NV | Macrocyclic inhibitors of mcl-1 |
JP2022540825A (ja) | 2019-07-09 | 2022-09-20 | ヤンセン ファーマシューティカ エヌ.ベー. | Mcl-1阻害剤としての大環状スピロ環誘導体 |
US20220372014A1 (en) * | 2019-10-01 | 2022-11-24 | The Johns Hopkins University | Neuroprotective compounds and methods of use thereof |
WO2021092061A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Combination treatment for senescence-associated diseases |
WO2021092053A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
WO2021099579A1 (en) | 2019-11-21 | 2021-05-27 | Janssen Pharmaceutica Nv | Macrocyclic indole derivatives as mcl-1 inhibitors |
CN114728986A (zh) | 2019-11-21 | 2022-07-08 | 詹森药业有限公司 | 作为mcl-1抑制剂的大环磺酰基衍生物 |
CA3162963A1 (en) * | 2019-12-18 | 2021-06-24 | Zeno Management, Inc. | Macrocyclic compounds |
KR20220143906A (ko) | 2020-02-21 | 2022-10-25 | 얀센 파마슈티카 엔.브이. | Mcl-1의 억제제로서의 거대환식 인돌 유도체 |
CN115335384A (zh) * | 2020-03-30 | 2022-11-11 | 江苏恒瑞医药股份有限公司 | 一种吲哚类大环衍生物的结晶形式及其制备方法 |
CA3178283A1 (en) | 2020-05-29 | 2021-12-02 | Frederik Jan Rita Rombouts | Macrocyclic 7-pyrazol-5-yl-indole derivatives as inhibitors of mcl-1 |
US20230234969A1 (en) | 2020-06-19 | 2023-07-27 | Janssen Pharmaceutica Nv | N-linked macrocyclic 7-(pyrazol-5-yl)-indole derivatives as inhibiors of mcl-1 |
EP4168413A1 (en) | 2020-06-19 | 2023-04-26 | JANSSEN Pharmaceutica NV | N-linked macrocyclic 4-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1 |
MX2023000438A (es) | 2020-07-08 | 2023-02-09 | Janssen Pharmaceutica Nv | Eter macrociclico que contiene derivados de indol como inhibidores de mcl-1. |
WO2022032284A1 (en) * | 2020-08-07 | 2022-02-10 | Zeno Management, Inc. | Macrocyclic compounds |
JP2023553808A (ja) | 2020-11-24 | 2023-12-26 | ノバルティス アーゲー | Mcl-1阻害剤抗体-薬物コンジュゲートおよび使用方法 |
EP4008324A1 (en) | 2020-12-07 | 2022-06-08 | Cellestia Biotech AG | Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer |
KR20230121807A (ko) | 2020-12-17 | 2023-08-21 | 얀센 파마슈티카 엔.브이. | Mcl-1의 억제제로서의 분지형 매크로사이클릭 4-(피라졸-5-일)-인돌유도체 |
MX2023009475A (es) | 2021-02-12 | 2023-08-22 | Janssen Pharmaceutica Nv | Derivados macrociclicos 1,3-con puente 6-cloro-7-pirazol-4-il-1h-i ndol-2-carboxilato y 6-cloro-7-pirimidina-5-il-1h-indol-2-carboxil ato como inhibidores de mcl-1 para el tratamiento del cancer. |
WO2022251247A1 (en) * | 2021-05-28 | 2022-12-01 | Zeno Management, Inc. | Macrocyclic compounds |
WO2022261301A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
AU2022290855A1 (en) | 2021-06-11 | 2023-12-07 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-body drug conjugates |
CN115490708A (zh) * | 2021-06-18 | 2022-12-20 | 苏州亚盛药业有限公司 | 磺酰胺类大环衍生物及其制备方法和用途 |
WO2023057484A1 (en) | 2021-10-06 | 2023-04-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy |
WO2023225359A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2009011210A (es) | 2007-04-16 | 2009-10-30 | Abbott Lab | Inhibidores de mcl1 de indol 7-no sustituido. |
MX2009011211A (es) * | 2007-04-16 | 2009-10-30 | Abbott Lab | Indoles sustituidos en la posicion 7 inhibidores de mci-1. |
BRPI0923567A2 (pt) * | 2008-12-22 | 2016-09-27 | Cubist Pharm Inc | agentes antibactericidas novos para o tratamento de infecções gram positivas |
JP5731538B2 (ja) * | 2009-12-23 | 2015-06-10 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | Crth2モジュレーター |
AU2012257513B2 (en) * | 2011-05-19 | 2017-05-11 | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Macrocyclic compounds as protein kinase inhibitors |
WO2014047427A2 (en) | 2012-09-21 | 2014-03-27 | Vanderbilt University | Substituted benzofuran, benzothiophene and indole mcl-1 inhibitors |
EP3038618B1 (en) | 2013-08-28 | 2020-10-14 | Vanderbilt University | Substituted indole mcl-1 inhibitors |
US9944656B2 (en) * | 2014-02-12 | 2018-04-17 | VIIV Healthcare UK (No.5) Limited | Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication |
CA2943815C (en) | 2014-03-27 | 2023-04-04 | Vanderbilt University | Substituted indole mcl-1 inhibitors |
JP6605493B2 (ja) * | 2014-04-11 | 2019-11-13 | バイエル ファーマ アクチエンゲゼルシャフト | 新規大環状化合物 |
US9949965B2 (en) | 2014-10-17 | 2018-04-24 | Vanderbilt University | Tricyclic indole Mcl-1 inhibitors and uses thereof |
KR102388208B1 (ko) | 2016-04-22 | 2022-04-18 | 아스트라제네카 아베 | 암을 치료하기 위한 거대 환형 mcl1 억제제 |
-
2017
- 2017-04-21 KR KR1020187033540A patent/KR102388208B1/ko active IP Right Grant
- 2017-04-21 AR ARP170101026A patent/AR108301A1/es unknown
- 2017-04-21 MX MX2018012711A patent/MX2018012711A/es unknown
- 2017-04-21 JP JP2018553226A patent/JP6894449B2/ja active Active
- 2017-04-21 CA CA3020378A patent/CA3020378A1/en active Pending
- 2017-04-21 CO CONC2018/0008759A patent/CO2018008759A2/es unknown
- 2017-04-21 RS RS20200549A patent/RS60257B1/sr unknown
- 2017-04-21 US US15/493,210 patent/US9840518B2/en active Active
- 2017-04-21 AU AU2017252222A patent/AU2017252222B2/en active Active
- 2017-04-21 EP EP17720720.6A patent/EP3445767B1/en active Active
- 2017-04-21 EA EA201892300A patent/EA036551B1/ru not_active IP Right Cessation
- 2017-04-21 BR BR112018070677-9A patent/BR112018070677B1/pt active IP Right Grant
- 2017-04-21 SG SG11201805838UA patent/SG11201805838UA/en unknown
- 2017-04-21 TN TNP/2018/000319A patent/TN2018000319A1/en unknown
- 2017-04-21 PE PE2018001558A patent/PE20181803A1/es unknown
- 2017-04-21 TW TW106113380A patent/TWI742074B/zh active
- 2017-04-21 HU HUE17720720A patent/HUE049591T2/hu unknown
- 2017-04-21 ME MEP-2020-99A patent/ME03729B/me unknown
- 2017-04-21 ES ES17720720T patent/ES2791319T3/es active Active
- 2017-04-21 SI SI201730246T patent/SI3445767T1/sl unknown
- 2017-04-21 PT PT177207206T patent/PT3445767T/pt unknown
- 2017-04-21 WO PCT/EP2017/059511 patent/WO2017182625A1/en active Application Filing
- 2017-04-21 MA MA44721A patent/MA44721B1/fr unknown
- 2017-04-21 LT LTEP17720720.6T patent/LT3445767T/lt unknown
- 2017-04-21 CR CR20180499A patent/CR20180499A/es unknown
- 2017-04-21 DK DK17720720.6T patent/DK3445767T3/da active
- 2017-04-21 CN CN201780022366.0A patent/CN109071566B/zh active Active
- 2017-04-21 PL PL17720720T patent/PL3445767T3/pl unknown
- 2017-10-23 US US15/790,660 patent/US10196404B2/en active Active
-
2018
- 2018-08-23 CL CL2018002410A patent/CL2018002410A1/es unknown
- 2018-09-12 SV SV2018005742A patent/SV2018005742A/es unknown
- 2018-09-25 NI NI201800093A patent/NI201800093A/es unknown
- 2018-10-05 DO DO2018000222A patent/DOP2018000222A/es unknown
- 2018-10-09 IL IL262237A patent/IL262237B/en unknown
- 2018-10-18 PH PH12018502227A patent/PH12018502227A1/en unknown
- 2018-11-19 ZA ZA2018/07766A patent/ZA201807766B/en unknown
- 2018-12-18 US US16/223,538 patent/US10889594B2/en active Active
-
2020
- 2020-04-28 HR HRP20200673TT patent/HRP20200673T1/hr unknown
- 2020-05-14 CY CY20201100443T patent/CY1123186T1/el unknown
- 2020-12-04 US US17/111,896 patent/US11472816B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201807766B (en) | Macrocyclic mcl1 inhibitors for treating cancer | |
HK1251407A1 (zh) | 治療癌症的方法 | |
ZA201706616B (en) | Method for treating cancer | |
IL304252A (en) | Cancer treatment methods | |
IL289947A (en) | A method for treating cancer | |
HK1249469A1 (zh) | 用RORγ抑制劑治療癌症的方法 | |
IL257691A (en) | A method for treating cancer | |
HK1250944A1 (zh) | 用於治療癌症的方法 | |
ZA201900052B (en) | Pharmaceutical combinations for treating cancer | |
HK1250942A1 (zh) | 用於治療癌症的方法 | |
HK1250943A1 (zh) | 用於治療癌症的方法 | |
SG10201508795XA (en) | Method for treating cancer | |
IL265537A (en) | Methods of treating ovarian cancer |